手机购彩

The company's inhaled halothane was approved for sale in the U.S. and four products including iodixanol obtained the EU drug GMP certificate
Recently, Hengrui Medicine received a notification from the US Food and Drug Administration (FDA) that halothane for inhalation was approved for sale in the United States. The original desflurane trade name is Suprane, which is suitable for maintaining anesthesia for inpatient and outpatient adult, infant, and child surgery patients. In the first three quarters of 2017, the global market sales of desflurane were about US $ 200 million. Currently, in addition to the original research company Baxter in the United States and China, desflurane generic drugs have been approved for listing.
2018-03-14
Hengrui Pharmaceutical's 2017 annual work summary and commendation ceremony was grandly held
China Hengrui, the world Hengrui. On the afternoon of February 12, the 2017 annual work summary and commendation meeting of Jiangsu Hengrui Pharmaceutical Co., Ltd. was grandly held in Haizhou Bay Convention Center. Chairman Sun Piaoyang of the company attended the meeting and made an important speech. General Manager Zhou Yunshu made the company's work report for 2017. Ms. Jiang Sumei, the executive deputy general manager chaired the meeting and read out the commendation decision. More than 600 leaders from Jiangsu Hengrui and related subsidiaries and above officials Attend a meeting.
2018-02-24
Secretary of the Municipal Party Committee Yang Shenglai came to visit and condolences high-level talents
The Spring Festival is approaching. On the morning of February 12, the Secretary of the Municipal Party Committee Yang Shengshi came to Jiangsu Hengrui Pharmaceutical Co., Ltd. to visit and condone the company's high-level talents, and to extend holiday greetings and best wishes to them on behalf of the Municipal Party Committee and Municipal Government. City leaders Cao Weidong and Wang Dongsheng attended the condolences.
2018-02-24
Hengrui Medicine Licensed JAK1 Inhibitor to Arcutis for US $ 223 Million Miles
On January 4, Hengrui Pharmaceutical and the American Arcutis Company reached an agreement in the United States. The company licensed the JAK1 inhibitor (code: "SHR0302") project with independent intellectual property rights for the treatment of immune system diseases with a mileage of US $ 223 million. Arcutis company. Arcutis will receive exclusive clinical development, registration, and marketing rights for JAK1 inhibitors for topical topical formulations for skin disease treatment in the US, EU, and Japan.
2018-01-29
Hengrui Medicine licenses BTK inhibitor to U.S. TG for $ 347 million in miles
On January 8th, Hengrui Pharmaceutical reached a license agreement with TG Therapeutics in the US. The company licensed the BTK inhibitors SHR1459 and SHR1266 with independent intellectual property rights to the US TG company for US $ 347 million in mileage. TG company will obtain its outside Asia In the region (but including Japan), the company has the exclusive clinical development and marketing rights of single or combined drugs to treat malignant hematological tumors. The company will work with TG to promote the development and listing of the project.
2018-01-29
Chairman of Hengrui Medicine Sun Piaoyang attended the meeting of the State Council
On August 25, Li Keqiang, member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, hosted a symposium to promote the construction of a strong manufacturing country and continue to promote the transformation and upgrading of the economic structure to study and deploy related work. Chairman of Hengrui Medicine Sun Piaoyang attended the meeting as a representative of the pharmaceutical industry.
2017-09-08
Hengrui Pharmaceutical docetaxel injection was approved for marketing in the U.S. and designated by the FDA as a reference standard preparation
Recently, the company received a notification from the US Food and Drug Administration (FDA) that three additional specifications of docetaxel injection have been finally approved by the US FDA and can be sold in the US market, respectively 20mg / 1mL, 80mg / 4mL, 160mg / 8mL, previously the product specification of 20mg / 0.5mL has been approved in the United States. According to the US FDA official website, the product's 40mg / ml specification is designated as the reference standard preparation (RS).
2017-08-23
上一页 1 ... 7 8 9 10 11 12 下一页 Total 95 records Previous 1 ... 7 8 9 10 11 12 Next